FORM 4

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| $\bigcirc$ | ΛD | AΡ | DD | $\sim$ | / A I |
|------------|----|----|----|--------|-------|
| ( )1       | ЛΚ | AΡ | РΚ | ( ) \  | /AI   |

| OMB Number:              | 3235-0287 |
|--------------------------|-----------|
| Estimated average burden |           |
| l                        | 0.5       |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 10b5-1(c). See I   | nstruction 10.                               |       |   |  |
|--|--|-------|---|--|
| Name and Address of Reporting Person*  Evans Carl Anthony              |  |       | 2. Issuer Name and Ticker or Trading Symbol <u>CNS Pharmaceuticals, Inc.</u> [ CNSP ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  |
| (Last)   | ) (First) (Middle) CNS PHARMACEUTICALS, INC. |       | 3. Date of Earliest Transaction (Month/Day/Year) 04/08/2024                           | X Director 10% Owner Officer (give title Other (specify below) below)  |
| C/O CNS PHARMACEUTICALS, INC. 100 WEST LOOP SOUTH, SUITE 900  (Street) |  |       | If Amendment, Date of Original Filed (Month/Day/Year)                                 | Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |
| HOUSTON  | TX   | 77027 |   |  |
| (City)   | (State)                                      | (Zip) |   |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| ( | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |       | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|--|---|--------------------------|---|--|---------------|-------|--|---|---|
|   |  |   | Code                     | v | Amount   | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)                                     |   | (111501.4)  |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (In<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | Reported                     | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|---------------------------------|---|--|-----|--|--------------------|--|-------------------------------------|---|------------------------------|--|---------------------------------------|
|   |   |  |   | Code                            | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |   | Transaction(s)<br>(Instr. 4) |  |                                       |
| Option to purchase common stock                     | \$0.2586  | 04/08/2024                                 |   | A                               |   | 17,500   |     | (1)  | 04/08/2034         | Common<br>Stock  | 17,500                              | (2)   | 129,594                      | D  |                                       |
| Restricted Stock<br>Units                           | (3)   | 04/08/2024                                 |   | A                               |   | 17,500   |     | (1)  | (1)                | Common<br>Stock  | 17,500                              | (2)   | 147,094                      | D  |                                       |

#### Explanation of Responses:

- 1. The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.
- 2. The awards were issued in connection with the reporting person's Board of Director services to the Company.
- 3. Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

/s/ Christopher Downs, Attorney-in-fact

04/10/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.